Drug Profile
Research programme: anti-inflammatory therapeutics - Omeros Corporation
Alternative Names: anti-MASP-2 monoclonal antibody - Omeros Corporation; MASP-2 therapeutics - Omeros Corporation; MASP-3 therapeutics - Omeros CorporationLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Omeros Corporation
- Class Anti-inflammatories; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies; Small molecules; Vascular disorder therapies
- Mechanism of Action Mannose binding protein associated serine protease inhibitors; MASP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute kidney injury; Age-related macular degeneration; Haemolytic uraemic syndrome; Inflammation; Myocardial reperfusion injury; Paroxysmal nocturnal haemoglobinuria; Reperfusion injury; Stroke
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Acute kidney injury in USA (Intraperitoneal, Injection)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Parenteral)
- 28 Apr 2022 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in USA (SC)